🇺🇸 FDA

Company profile · Sponsor

Gruenenthal

Gruenenthal GmbH

E8C4ECE · EMA pharma EU
Pipeline
3
Drugs
0
Patents
0

Quick answer

Gruenenthal (E8C4ECE) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E8C4ECE
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (3)

Search pipeline →

  1. RTX-GRT7039, Naropin® 5 mg/ml Injektionslösung

    Gruenenthal

    Moderate to severe pain associated with Osteoarthritis of the knee

    phase 3 small molecule active

    1 trial

  2. A randomized, single-center, double-blind, placebo-controlled, first-in-human trial with single and multiple ascending doses to determine safety, tolerability, and pharmacokinetics of GRT7040 in healthy volunteers

    Gruenenthal

    Treatment of pain

    phase 1 other active

    1 trial

  3. A trial to investigate the safety and pharmacokinetics of GRT6019 in healthy male participants.

    Gruenenthal

    Not applicable for phase I study

    phase 1 other active

    1 trial

Frequently asked questions

What is Gruenenthal?

Gruenenthal (E8C4ECE) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Gruenenthal sponsor?

We track 3 ClinicalTrials.gov-linked programs for Gruenenthal, including RTX-GRT7039, Naropin® 5 mg/ml Injektionslösung and 2 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Gruenenthal company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.